Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest Must Resolve Breakpoint Issues On Road To Ceftaroline Approval

Executive Summary

Negotiation of breakpoints appears to be the final hurdle as Forest Laboratories seeks approval for ceftaroline fosamil to treat serious skin infections and community-acquired bacterial pneumonia.

You may also be interested in...



FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline

FDA demonstrated a willingness to be flexible about antibiotic breakpoints in its Oct. 29 approval of Forest Laboratories' ceftaroline fosamil.

FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline

FDA demonstrated a willingness to be flexible about antibiotic breakpoints in its Oct. 29 approval of Forest Laboratories' ceftaroline fosamil.

FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says

The new endpoint proposed in FDA’s recent acute bacterial skin and skin structure infections guidance – cessation of lesion spread – needs further refinement to be a reliable assessment of antibiotic efficacy, according to members of the agency’s Anti-Infective Drugs Advisory Committee.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel